News
Study Published in European Society for Medical Oncology (ESMO) Open Highlights Preliminary Clinical Activity of Aminex Therapeutics’ Dual Agent Immunotherapy Treatment Approach
Journal of Molecular Oncology confirms synergistic effects of the Aminex Therapeutics drug AMXT 1501 combined with DFMO
A new peer reviewed report in the journal Molecular Oncology confirms the synergistic effects of the Aminex Therapeutics drug AMXT 1501 combined with DFMO in disrupting the polyamine pathway in Neuroblastoma. Neuroblastoma is a type of cancer affecting nerve cells, primarily afflicts children under the age of 5, and is highly dependent on polyamines to grow and multiply. When DFMO disrupts polyamine biosynthesis in neuroblastoma cells, these cells compensate by increasing their uptake of polyamines from the bloodstream. This article describes how AMXT 1501 inhibits this polyamine uptake and diminishes neuroblastoma cell growth.
The International Journal of Cancer publishes peer reviewed study showing the positive impacts of the Aminex drug AMXT 1501 combined with DFMO in targeting acute leukemia.
The International Journal of Cancer has published a peer reviewed study showing the positive impacts of the Aminex drug AMXT 1501 combined with DFMO in targeting acute leukemia. A pre-clinical study sponsored by the Children’s Cancer Institute in Sydney, Australia showed that the combination of these two drugs synergistically inhibit the growth of acute leukemia cell lines by inducing apoptosis (cancer cell death), even when treatment was initiated at high disease burden. The study supports further preclinical and clinical investigation into this treatment approach for acute leukemia.
Aminex Announces Appointment of David Meeks as Executive Chairman of the Board of Directors
Aminex completes Phase 1a portion of clinical trial evaluating AMXT-1501 and DFMO
Aminex Enrolls First Patient in Phase 1B Trial of AMXT-1501 and DFMO
Aminex Therapeutics Completes Enrollment in Phase 1A portion of Clinical Trial Evaluating AMXT 1501 and DFMO
Sydney Researchers Identify Potential New Drug Treatment Developed by Aminex Therapeutics for Fatal Childhood Cancer
International Research Team Led by Australian Scientists Discover a Potential Way to Treat and Prevent Cancer in Children with Neuroblastoma
Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients
Aminex Therapeutics, Inc. Closes $4M Series A Financing